| Date | Title | | | 11/28/07 | Inspire Initiates Phase 3 Trial of Epinastine Nasal Spray for Allergic Rhinitis| Top-line Results Expected Second Quarter 2008
DURHAM, N.C.--(BUSINESS WIRE)--Nov. 28, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the initiation of
a Phase 3 clinical trial to evaluate epinastine nasal spray for the
treatment of seasonal allergic rhinitis.
This Phase 3 clinical trial is a 14-day randomized, double-blind
comparison of two concentrations of epinastine (0.1% and 0.15%) at two
different spray volumes to placebo in approximately 750 subjects ... |
|  | | 11/09/07 | Inspire Announces Oral Presentation of Phase 2 Epinastine Nasal Spray Data at American College of Allergy, Asthma & Immunology Meeting| DURHAM, N.C.--(BUSINESS WIRE)--Nov. 9, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that a
presentation of its Phase 2 clinical trial data on epinastine nasal
spray for the treatment of allergic rhinitis will be given during the
American College of Allergy, Asthma & Immunology (ACAAI) 2007 Annual
Meeting on November 8 - 11, 2007 in Dallas. The oral presentation by
Paul H. Ratner, M.D., M.B.A., will occur on November 11th at 1:00 p.m.
and is based on data contained... |
| | | 11/07/07 | Inspire Reports Third Quarter 2007 Financial Results| -Third Quarter Revenue Up 26% -
DURHAM, N.C.--(BUSINESS WIRE)--Nov. 7, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results
for the third quarter ended September 30, 2007, reporting a 26%
increase in third quarter revenues as compared to 2006 and a net loss
of $13.7 million, or ($0.32) per share.
In August 2007, Inspire launched AzaSite(TM) (azithromycin
ophthalmic solution) 1% in the United States for the treatment of
bacterial conjunctivitis.... |
| | | 11/01/07 | Inspire Stockholders Approve Exchange of Preferred Stock Related to Warburg Pincus Investment| DURHAM, N.C.--(BUSINESS WIRE)--Nov. 1, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today the results from
its Special Meeting of Stockholders, held on October 31, 2007. The
Company's stockholders approved the proposal to exchange 140,186
shares of Series A Exchangeable Preferred Stock, issued and sold to
the Warburg Pincus Private Equity IX Fund in July 2007, into
14,018,600 shares of common stock.
The Company now has 56,439,001 shares of common stock outstanding
... |
| | | 10/24/07 | Inspire Announces Date for Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 24, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that it plans to
report third quarter 2007 financial results on Wednesday, November 7,
2007 before the market opens. Inspire's President and CEO, Christy L.
Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host
a conference call and live webcast on Wednesday, November 7, 2007 at
10:00 a.m. ET.
To access the conference call, U.S. participants may call (877)
648... |
| | | 10/04/07 | Inspire Completes Enrollment in Phase 3 Cystic Fibrosis Trial| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 4, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it has
completed patient enrollment in TIGER-1, the first of two planned
pivotal Phase 3 clinical trials with denufosol tetrasodium inhalation
solution for the treatment of cystic fibrosis (CF). The Company
expects top-line efficacy data from TIGER-1 to be available mid-year
2008, which is earlier than previously projected.
TIGER-1, initiated in July 2006, is a double-bli... |
| | | 10/03/07 | Inspire Announces Poster Presentations at the 2007 North American Cystic Fibrosis Conference| DURHAM, N.C.--(BUSINESS WIRE)--Oct. 3, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire
scientists, clinical investigators and collaborators will present
information from four abstracts in poster presentations during the
21st Annual North American Cystic Fibrosis (NACF) Conference at the
Anaheim Convention Center in California on October 3-6, 2007.
Two of the four abstracts contain data from Inspire's Phase 2
clinical trials with denufosol for the tr... |
| | | 09/18/07 | Inspire Announces Webcast of Presentation at the UBS 2007 Global Life Sciences Conference| DURHAM, N.C.--(BUSINESS WIRE)--Sept. 18, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Thomas R.
Staab, II, Chief Financial Officer, will present at the UBS 2007
Global Life Sciences Conference on Tuesday, September 25, 2007 at 3:30
pm ET in New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this link for a limited
... |
| | | 08/30/07 | Inspire Announces Webcast of Presentation at the Thomas Weisel Annual Healthcare Conference| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 30, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L.
Shaffer, Ph.D., President and CEO, and Joseph K. Schachle, Executive
Vice President and Chief, Commercial and Corporate Operations, will
present at the Thomas Weisel Annual Healthcare Conference on Thursday,
September 6, 2007 at 4:25 pm ET in Boston, MA.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived... |
| | | 08/13/07 | Inspire Pharmaceuticals Launches AzaSite(TM) in the United States for Ocular Infections| DURHAM, N.C.--(BUSINESS WIRE)--Aug. 13, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the U.S. launch
and commercial availability of AzaSite(TM)(azithromycin ophthalmic
solution) 1% for the treatment of bacterial conjunctivitis. AzaSite
has been shipped to pharmacies throughout the United States and
Inspire's sales force of 98 sales representatives has begun product
education outreach to physicians.
AzaSite offers the fewest number of doses for the treatment o... |
| | | 08/08/07 | Inspire Reports Second Quarter 2007 Financial Results| Launching AzaSite(TM) on August 13th
DURHAM, N.C.--(BUSINESS WIRE)--Aug. 8, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results
for the second quarter ended June 30, 2007, reporting a net loss of
$5.9 million, or ($0.14) per share.
Total revenue for the second quarter of 2007 was $15.4 million, as
compared to $13.4 million for the second quarter of 2006. Co-promotion
revenue from net sales of Elestat(R) (epinastine HCl ophthalmic
solution) 0.0... |
| | | 07/25/07 | Inspire Announces Date for Conference Call and Webcast to Discuss Second Quarter 2007 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--July 25, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to
report second quarter 2007 financial results on Wednesday, August 8,
2007 before the market opens. Inspire's President and CEO, Christy L.
Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II, will host
a conference call and live webcast on Wednesday, August 8, 2007 at
10:00 a.m. ET.
To access the conference call, U.S. participants may call (877)
648... |
| | | 07/18/07 | Inspire Announces $75 Million Financing with Warburg Pincus| DURHAM, N.C.--(BUSINESS WIRE)--July 18, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it has
entered into a securities purchase agreement for the sale of $75
million of exchangeable preferred stock to Warburg Pincus, a leading
global private equity investor. The transaction was based on a price
of $5.35 per common share and is expected to close this week.
Inspire plans to use the proceeds from the financing to fund
AzaSite(TM) commercialization and severa... |
| | | 07/11/07 | Inspire to Advance Epinastine Nasal Spray to Phase 3| DURHAM, N.C.--(BUSINESS WIRE)--July 11, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced plans to proceed to a
Phase 3 clinical program to evaluate epinastine nasal spray for the
treatment of allergic rhinitis, following a productive End-of-Phase 2
meeting with the U.S. Food and Drug Administration (FDA).
"We are pleased to be advancing the clinical program for
epinastine nasal spray," stated Christy L. Shaffer, Ph. D., President
and CEO of Inspire. "Based on the FDA's... |
| | | 07/03/07 | Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference| DURHAM, N.C.--(BUSINESS WIRE)--July 3, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L.
Shaffer, Ph.D., President and CEO, will present at the C.E. Unterberg,
Towbin Emerging Growth Opportunities Conference on Wednesday, July 11,
2007 at 11:00 am ET in New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this lin... |
| | | 06/21/07 | Inspire Announces Webcast of Presentation at Jefferies Healthcare Conference| DURHAM, N.C.--(BUSINESS WIRE)--June 21, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas R.
Staab, II, Chief Financial Officer and Treasurer, and Donald J.
Kellerman, Pharm.D., Senior Vice President, Development, will present
at the Jefferies Healthcare Conference on Thursday, June 28, 2007 at
1:30 pm ET in New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast... |
| | | 06/20/07 | Inspire and FAES Farma Amend Bilastine Licensing Agreement| DURHAM, N.C.--(BUSINESS WIRE)--June 20, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) and FAES Farma, S.A. have amended
their licensing agreement for the U.S. and Canadian development and
commercialization of oral bilastine for the treatment of allergic
rhinitis, based on a meeting with the Pulmonary Division of the U.S.
Food and Drug Administration (FDA) in which the existing clinical data
and recent QT/QTc trial results were discussed.
In consultation with Inspire, FAES has... |
| | | 06/12/07 | Inspire Announces Presentations at Two European Scientific Conferences| DURHAM, N.C.--(BUSINESS WIRE)--June 12, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists
and collaborators related to Inspire will present information at the
XXVI Congress of the European Academy of Allergology and Clinical
Immunology (EAACI) being held June 9-13, 2007 in Goteborg, Sweden and
at the 30th European Cystic Fibrosis Society (ECFS) Conference being
held June 13-16, 2007 in Belek, Turkey.
The EAACI Congress includes two presentations wi... |
| | | 06/07/07 | Inspire Adds Stephen D. Celestini as Senior Vice President and Chief Compliance Officer| DURHAM, N.C.--(BUSINESS WIRE)--June 7, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the hiring of
Stephen D. Celestini as Senior Vice President and Chief Compliance
Officer, reporting to Inspire's President and CEO, Christy L. Shaffer,
Ph.D.
"We are extremely pleased to have Steve join the Inspire team,"
stated Christy L. Shaffer, President and CEO of Inspire. "Steve has
valuable experience in leading compliance programs, in particular for
companies with mar... |
| | | 05/29/07 | Inspire Announces Webcast of Presentation at FTN Midwest Securities Health Care Conference| DURHAM, N.C.--(BUSINESS WIRE)--May 29, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Thomas R.
Staab, II, Chief Financial Officer and Treasurer, and Benjamin R.
Yerxa, Ph.D., Chief Scientific Officer and Executive Vice President,
Strategic Operations, will present at the FTN Midwest Securities
Health Care Conference on Tuesday, June 5, 2007 at 9:35 am ET in New
York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspi... |
| | | 05/09/07 | Inspire Reports First Quarter 2007 Financial Results|
Q1 2007 Co-promotion Revenue Up 71% over Q1 2006
2007 Financial Outlook Revised
DURHAM, N.C.--(BUSINESS WIRE)--May 9, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results
for the first quarter ended March 31, 2007, reporting a net loss of
$26.1 million, or ($0.62) per share.
Total revenue for the first quarter of 2007 was $7.2 million,
generated entirely from co-promotion activities, compared to $5.5
million for the fi... |
| | | 05/08/07 | Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis| DURHAM, N.C.--(BUSINESS WIRE)--May 8, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced results of a
Phase 2 dose-ranging clinical trial comparing epinastine nasal spray
and placebo in patients with seasonal allergic rhinitis. For the
primary endpoint of improvement in total nasal symptom score,
dose-related effects were observed in the trial, with the higher dose
(0.1%) achieving statistical superiority over placebo.
Christy L. Shaffer, Ph.D., Inspire's President... |
| | | 05/04/07 | Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting| DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists
and collaborators related to Inspire will present information from
five abstracts at the 2007 Association for Research in Vision and
Ophthalmology (ARVO) Annual Meeting to be held May 6-10, 2007 in Ft.
Lauderdale, Florida. These abstracts, which will be presented in
poster sessions, are related to three of Inspire's programs, including
bacterial conjunctivitis, dry ... |
| | | 04/27/07 | Inspire Announces FDA Approval Of AzaSite(TM)|
New Product Provides Convenient Treatment for Bacterial
Conjunctivitis
Conference Call Scheduled for Monday, April 30, 2007 at 9:00 AM ET
DURHAM, N.C.--(BUSINESS WIRE)--April 27, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that the U.S.
Food and Drug Administration (FDA) has approved AzaSite(TM)
(azithromycin ophthalmic solution) 1% for the treatment of bacterial
conjunctivitis. Inspire anticipates launching AzaSite in the... |
| | | 04/26/07 | Inspire Announces Webcasts of Presentations at Deutsche Bank and Morgan Stanley Healthcare Conferences| DURHAM, N.C.--(BUSINESS WIRE)--April 26, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced that senior executives
from the Company will present at the Deutsche Bank Securities 32nd
Annual Health Care Conference on Wednesday, May 2, 2007 at 11:15 a.m.
ET in Washington, D.C. and at the Morgan Stanley Global Healthcare
Unplugged Conference on Thursday, May 3, 2007 at 8:00 a.m. ET in
Miami, Florida.
Webcasts of these presentations will be available on Inspire's web
site at... |
| | | 04/25/07 | Inspire Announces Date for Conference Call and Webcast to Discuss First Quarter 2007 Financial Results| DURHAM, N.C., Apr 25, 2007 (BUSINESS WIRE) -- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that
it plans to report first quarter 2007 financial results on Wednesday,
May 9, 2007 before the market opens. Inspire's President and CEO,
Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R. Staab, II,
will host a conference call and live webcast on Wednesday, May 9, 2007
at 10:00 a.m. ET.
DATE: Wednesday, May 9, 2007
TIME: 10:00 a.m. ET
WEBCAST: Li... |
| | | 03/06/07 | Inspire Announces Webcast of Presentation at Cowen and Company's 27th Annual Health Care Conference| DURHAM, N.C.--(BUSINESS WIRE)--March 6, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Christy L.
Shaffer, Ph.D., President and CEO, will present at Cowen and Company's
27th Annual Health Care Conference on Tuesday, March 13, 2007 at 9:30
am ET in Boston.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived version of the webcast
presentation will also be available through this link for a limited
tim... |
| | | 02/27/07 | Inspire Reports Fourth Quarter and Full Year 2006 Financial Results| 2006 Revenue up 59% over 2005
DURHAM, N.C.--(BUSINESS WIRE)--Feb. 27, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results
for the fourth quarter and year ended December 31, 2006, reporting a
net loss of $15.5 million, or ($0.37) per share, for the fourth
quarter, and a net loss of $42.1 million, or ($1.00) per share, for
the full year.
Total revenue for the fourth quarter of 2006 was $8.5 million,
which was generated from co-promotion activiti... |
| | | 02/23/07 | Inspire to Present Data at 2007 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 23, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire
scientists and collaborators will present information at the 2007
American Academy of Allergy, Asthma & Immunology (AAAAI) Annual
Meeting being held February 23 - 27, 2007 in San Diego.
A podium presentation entitled "Anticholinergic Effects of
Antihistamine Drugs Used in the Clinic" will be presented by Inspire
scientist, Samuel C. Wolff, Ph.D., on Sunday, Febru... |
| | | 02/22/07 | Inspire Announces Webcast of Presentation at Susquehanna Healthcare Conference| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 22, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Thomas R.
Staab, II, Chief Financial Officer and Treasurer, and Donald J.
Kellerman, Pharm.D., Senior Vice President, Development, will present
at Susquehanna Financial Group's Healthcare Conference on Thursday,
March 1, 2007 at 10:00 am ET in New York City.
The webcast of the presentation will be available on Inspire's web
site at www.inspirepharm.com. An archived versi... |
| | | 02/20/07 | Inspire Announces Executive Management Promotions| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 20, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the following
executive management promotions.
Benjamin R. Yerxa, Ph.D. has been promoted to Chief Scientific
Officer and Executive Vice President, Strategic Operations, from
Chief, Strategic Operations and Alliances.
Joseph K. Schachle has been promoted to Executive Vice President
and Chief, Commercial Operations, from Senior Vice President,
Marketing and Sales.
Ge... |
| | | 02/16/07 | Inspire Licenses AzaSite(TM) For Ocular Infections|
Leverages Commercial Infrastructure with Novel Ocular
Anti-Infective Product
AzaSite(TM) New Drug Application Currently Under Review by FDA
with PDUFA Date in April
Conference Call Scheduled Today at 10:00 AM ET
DURHAM, N.C.--(BUSINESS WIRE)--Feb. 16, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the signing of an
exclusive licensing agreement with InSite Vision Incorporated (AMEX:... |
| | | 02/13/07 | Inspire Director Alan F. Holmer Resigns Board Position to Accept Senior Post in Bush Administration| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 13, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Alan F.
Holmer has resigned from the Board of Directors of Inspire
Pharmaceuticals, Inc., effective February 13, 2007, to accept an
appointment in the Bush Administration. Secretary of the Treasury,
Henry M. Paulson, Jr., announced that he has appointed Ambassador
Holmer as his Special Envoy for China and the Strategic Economic
Dialogue. In his new role, he will lead the Adm... |
| | | 02/13/07 | Inspire Announces Date for Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2006 Financial Results| DURHAM, N.C.--(BUSINESS WIRE)--Feb. 13, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that it plans to
report fourth quarter and full year 2006 financial results on Tuesday,
February 27, 2007 before the market opens. Inspire's President and
CEO, Christy L. Shaffer, Ph.D., and CFO and Treasurer, Thomas R.
Staab, II, will host a conference call and live webcast on Tuesday,
February 27, 2007 at 10:00 a.m. ET.
DATE: Tuesday, February 27, 2007
TIME: ... |
| | | 01/16/07 | Inspire Provides Cystic Fibrosis Clinical Program Update| - Enrollment in TIGER-1 Trial Progressing Well -
DURHAM, N.C.--(BUSINESS WIRE)--Jan. 16, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced an update on its
clinical development program for denufosol tetrasodium for the
treatment of cystic fibrosis (CF).
"We continue to make good progress in the Phase 3 program for
denufosol," said Christy L. Shaffer, Ph.D., President and CEO of
Inspire. "Based on the number of sites that have been initiated and
current enroll... |
| | | 01/04/07 | Inspire Announces Dry Eye Program Update| DURHAM, N.C.--(BUSINESS WIRE)--Jan. 4, 2007--Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today an update in its
dry eye program.
Inspire provided additional information to the U.S. Food and Drug
Administration (FDA) in November 2006 related to Prolacria(TM) (the
proposed U.S. trade name for diquafosol tetrasodium ophthalmic
solution 2%). Inspire has been granted a meeting with the FDA to
continue discussions regarding Inspire's dry eye clinical program and
expects to p... |
| |
|
